Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

Kelvin Alexander Moses, MD, PhD, discusses relevant data and treatment decisions in metastatic hormone-sensitive prostate cancer, as well as the role of cytoreductive nephrectomy in RCC. 

David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.

Nancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Kathryn E. Beckermann, MD, PhD, discusses the available single-agent and combination options for the treatment of patients with metastatic renal cell carcinoma.

Daniel A. Barocas, MD, MPH, FACS, discusses the CEASAR study in prostate cancer, as well as therapeutic updates in renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses treatment selection in metastatic renal cell carcinoma.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

The optimal anticoagulant takes into consideration a variety of components, including patient preference, the indication for anticoagulation, comorbidities, reversibility, and other factors relevant to the clinical scenario.

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer.

Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.

Opioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses selecting the necessary inhibitor for patients with ALK-positive non-small cell lung cancer.

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Biliary tract cancers are rare but deadly diseases, subdivided into intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.

Pierre Massion, MD, on the necessity of having more people undergo lung cancer screening, ongoing clinical trials emphasizing the importance of early detection, and how to determine who is at highest risk for lung cancer.

Renal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).

Christine M. Lovly, MD, PhD, discusses the changing treatment landscape for patients with EGFR-mutant and ALK-positive NSCLC.